New clinical trial – Abraxane and carboplatin as first-line treatment for triple negative metastatic breast cancer


Duke University and Abraxis Bioscience recently started a phase II clinical trial involving Abraxane (nanoparticle albumin-bound paclitaxel), now registered in the Clinicaltrials.gov database under reference NCT01207102. The primary objective of the trial is to statistically test whether Abraxane and carboplatin can improve progression-free survival as first-line treatment for “triple negative” (no expression for estrogen, progesterone, or HER2 receptors) metastatic breast cancer. The study is not yet open for participant recruitment.

[[[ Additional links suggested by Nanocolors :

Nanoparticles & cancer therapy : volumetry in biomedical publications since 2000

Nanoparticles in clinical trial trends : comments & focus on Abraxane ]]]

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: